Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$8.49
-6.3%
$12.56
$0.88
▼
$17.25
$546.76M1.36356,700 shs277,967 shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.88
-1.4%
$6.53
$4.73
▼
$9.53
$716.31M0.41576,299 shs507,829 shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$9.01
-3.3%
$11.25
$7.82
▼
$17.25
$577M1.73573,016 shs168,162 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$3.58
-3.1%
$4.28
$2.40
▼
$5.47
$155.48M1.31213,280 shs224,685 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
+3.66%-13.88%-14.85%-33.87%+520.55%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-2.24%-1.83%+6.40%-10.51%+29.26%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-1.58%-11.91%-16.04%-37.83%+26.98%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-5.14%-8.44%-11.08%-23.28%+48.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$8.49
-6.3%
$12.56
$0.88
▼
$17.25
$546.76M1.36356,700 shs277,967 shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.88
-1.4%
$6.53
$4.73
▼
$9.53
$716.31M0.41576,299 shs507,829 shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$9.01
-3.3%
$11.25
$7.82
▼
$17.25
$577M1.73573,016 shs168,162 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$3.58
-3.1%
$4.28
$2.40
▼
$5.47
$155.48M1.31213,280 shs224,685 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
+3.66%-13.88%-14.85%-33.87%+520.55%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-2.24%-1.83%+6.40%-10.51%+29.26%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-1.58%-11.91%-16.04%-37.83%+26.98%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-5.14%-8.44%-11.08%-23.28%+48.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
2.86
Moderate Buy$29.50247.47% Upside
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
2.50
Moderate Buy$17.50154.25% Upside
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
2.89
Moderate Buy$18.57106.12% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ORMP, ANL, DSGN, and AURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Reiterated RatingMarket Outperform
11/5/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Lower Price TargetOutperform$20.00 ➝ $19.00
10/23/2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
UpgradeHold (C+) ➝ Buy (B-)
10/15/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Reiterated RatingSell (D-)
10/12/2026
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
Reiterated RatingSell (E+)
10/12/2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Reiterated RatingSell (D-)
10/5/2026
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
UpgradeStrong-Buy
10/2/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Initiated CoverageOverweight$26.00
10/2/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Initiated CoverageOverweight$26.00
9/10/2026
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
Initiated CoverageBuy$31.00
9/8/2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
Reiterated RatingHold (C+)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
$5M109.35N/AN/A($0.21) per share-40.43
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$2.76 per shareN/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$3.16 per shareN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M77.74$0.08 per share42.88$7.80 per share0.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
-$35.53MN/AN/AN/AN/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$106.19M-$1.64N/AN/AN/AN/A-64.68%-56.08%N/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$69.79M-$1.20N/AN/AN/AN/A-35.51%-33.35%N/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$64.05M$6.160.58N/AN/AN/A-6.97%-6.01%N/A

Latest ORMP, ANL, DSGN, and AURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.43$0.43N/A$0.43N/AN/A
11/9/2026Q3 2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.3681-$0.29+$0.0781-$0.29N/AN/A
11/4/2026Q3 2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.3441-$0.32+$0.0241-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.256.99%N/A4.06%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
0.04
9.55
N/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
14.20
14.21
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
16.78
16.78
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
6.07
4.98

Institutional Ownership

CompanyInstitutional Ownership
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
35.21%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%

Insider Ownership

CompanyInsider Ownership
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
N/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
1.90%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
17.10%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
20.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
10964.40 millionN/ANot Optionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
113104.07 million102.10 millionOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
6064.04 million53.09 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1343.49 million34.45 millionOptionable

Recent News About These Companies

No Recent Events Reported for Oramed Pharmaceuticals
Oramed: Q2 Earnings Snapshot
Oramed Pharmaceuticals Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adlai Nortye stock logo

Adlai Nortye NASDAQ:ANL

$8.49 -0.57 (-6.29%)
Closing price 03:58 PM Eastern
Extended Trading
$8.56 +0.06 (+0.77%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.88 -0.10 (-1.39%)
Closing price 03:58 PM Eastern
Extended Trading
$6.88 0.00 (-0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$9.01 -0.31 (-3.33%)
Closing price 03:58 PM Eastern
Extended Trading
$9.02 +0.01 (+0.11%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$3.58 -0.12 (-3.12%)
Closing price 03:59 PM Eastern
Extended Trading
$3.52 -0.05 (-1.51%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.